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ABSTRACT 
XIN ZOU: Using Aureochrome to Control Protein-protein Interactions with Light 
(Under the direction of Klaus Hahn) 
 
Protein-protein interactions occurring with precise timing and subcellular localization are 
critical for regulating various cellular behaviors, yet it is difficult to study these behaviors because 
there are no practical means to generate protein-protein interactions at precise times and places in live 
cells. Photoactivatable proteins provide a way to manipulate protein-protein interactions with light in 
vivo. Recently, a blue light receptor Aureochrome was discovered in stramenopile algae Vaucheria 
frigida. It has a basic region domain, leucine zipper domain and a LOV (Light, Oxygen, Voltage) 
domain. Blue light treatment strongly enhances Aureochrome binding to target DNA, implying that 
Aureochrome is a blue light-regulated transcription factor. To control protein-protein interactions by 
taking advantage of Aureochrome, we characterized the light-regulated dimerization of Aureochrome. 
With co-immunoprecipitation assays, we showed that a leucine zipper coupled with a LOV domain 
(F144-K348) is sufficient for light-dependent dimerization. Critical mutations or deletion of the 
leucine zipper destroy the dimerization, indicating that the leucine zipper domain is critical for 
dimerization. Mutation of the LOV domain also disrupts the response to light. Deletion of 25 amino 
acids at the C-terminus leads to light-independent dimerization, implying that an autoinhibition 
mechanism is involved. By introducing a salt bridge mutation in the leucine zipper domain, we are 
able to re-engineer Aureochrome to generate homodimerization rather than heterodimerization, which 
could potentially be valuable in many applications. Further to verification of the dimerization of 
AUREO1 in living cells, we expect AUREO1 to be useful for precisely controlling protein-protein 
interactions temporally and spatially with light.  
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CHAPTER 1 
BACKGROUND AND INTRODUCTION 
Proteins activities and protein-protein interactions are highly dynamics in living 
cells1,2. Precise control of proteins activities and their interactions are essential for regulating 
various cellular behaviors. Through perturbing cells and monitoring the response, we are able 
to study the role of proteins and their interaction. However, it remains difficult to control 
proteins activities or protein-protein interactions at precise times and places in live cells. 
Traditional methods, such as knockdown, knockout and exogenous expression, perturb 
protein activities in hours or even days. The application of these methods are greatly limited 
when they are used to study cell behaviors happening within minutes or even seconds, such 
as membrane ruffling, cell protrusion and migration3. Chemical induced dimerization has 
been widely used to regulate protein-protein interactions in living cells, especially control of 
signal transduction and transcription processes.4 For example, a Rapamycin-triggered 
heterodimerization strategy has been used to control protein dimerization in living cells to 
activate and inhibit small GTPase signaling pathways5,6. Rho GTPases were directly 
activated or inhibited within seconds, followed by cell morphological changes. However, it 
remains challenging to control proteins dynamics spatially within subcellular dimensions. 
Cell behaviors are not only controlled by proteins activities but also regulated by localization. 
Therefore, although chemical-induced protein dimerization methods have provided new ways 
to perturb biological systems, lack of tissue specificity and temporal resolution restricted by 
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cell permeation and diffusion limit applications.  Besides, it could be difficult to deliver 
molecules for these methods to tissues for in vivo studies. A system that is able to control 
protein activities or protein-protein interactions with high temporal and spatial resolution will 
benefit cell behavior research tremendously. 
Recently, genetically encoded light regulated systems have been developed based on 
plant photoreceptors. One such system7 is based on the LOV (light, oxygen and voltage) 
domain from phototropin8,9. Rac1 mutants were fused to the LOV domain and were sterically 
blocked by the LOV domain until blue light irradiation. Upon blue light activation, 
photoactivatable Rac1 (PA-Rac1) could generate precisely localized cell protrusions and 
membrane ruffling. Localized Rac1 activation by laser was sufficient to drive directed cell 
migration. This system could be applied to Cdc42, but not to RhoA, which is also in the Rho 
family. Proper three dimensional orientations between the LOV domain and the fused protein 
are required and limit the extension of this photoactivation approach to other proteins with 
very different three dimensional structures. 
Light regulated protein-protein interactions via genetically encoded dimerization 
based on plant domains are also being developed in different labs10-13. One of them is based 
on the Arabidopsis thaliana photoreceptor phytochrome B (PhyB) and phytochrome 
interaction factor 3 (PIF3), which dimerize upon red light illumination and dissociate upon 
far-red light illumination. Despite the rapid reversibility of dimerization with far-red light 
illumination, this system requires a bilin cofactor found only in plants and some light-sensing 
lower organisms, limiting the application to other organisms as the cofactor needs be added 
exogenously, especially for in vivo studies. Another system took advantage of the light-
dependent dimerization of FKF1 and GI, two proteins that control flowering in Arabidopsis 
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thaliana11. FKF1 contains a LOV domain which responds to light via a flavin 
mononucleotide (FMN). Blue light illumination induces formation of a covalent bond 
between FMN and cysteine 91 of FKF1, leading FKF1 to bind to protein GI9. Although this 
system does not need exogenous chromophore, the kinetics of the dimerization are slow, 
requiring tens of minutes11. In 2010, Kennedy et al developed a rapid light-regulated 
dimerization system based on a basic helix-loop-helix protein Arabidopsis CIB1 and 
cryptochrome 2 (CRY2)14. No exogenous cofactors are required for the system. The response 
upon light activation happens within seconds and the dimerization is reversible. Although the 
CIB1 and CRY2 are a little oversized, this system provides a very powerful potential 
platform for controlling a wide range of protein-protein interactions.  
Recently, a blue light receptor Aureochrome was discovered in stramenopile algae 
Vaucheria frigida15. Two homologs, AUREO1 and AUREO2, were identified. They were 
composed of 348 and 343 amino acids, respectively. Each has one putative basic 
region/leucine zipper (bZIP) transcription-regulation domain and a single LOV domain near 
the C-terminus (Figure 1A). The LOV domains of AUREO1 and AUREO2 are similar to the 
LOV1 and LOV2 domains from plant phototropins. 11 and 9 conserved amino acids residues 
necessary for the FMN binding and cysteinyl adduct formation16  were found in AUREO1 
and AUREO2 respectively, indicating that these proteins may functions as photoreceptors 
(Figure 1B15).  
AUREO1 binds flavin mononucleotide (FMN) via its LOV domain, possibly forming 
a cysteinyl adduct to the C94a carbon of the FMN upon light activation. This process is 
reversible, with a half-life of around 5 minutes. Gel shift assays showed that AUREO1 binds 
to DNA upon light activation, indicating that AUREO1 functions as a transcription factor 
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which is regulated by light. However, AUREO2 does not rely on light activation. Besides, 
transcription factors with bZIP domains usually bind to DNA by forming 
 
Figure 1 Structure and aligned sequences of Aureochromes from V. frigida. A, basic 
region/leucine zipper (bZIP) and LOV domains are colored red and blue, respectively. B, 
sequence alignment of AUREO1 and AUREO2. bZIP and LOV domains are indicated with 
red and blue frames, respectively. Basic amino acids are colored in orange and heptad leucine 
residues of bZIP domains are colored in red. The asterisks indicate identical amino acids 
between AUREO1 and AUREO214.  
 
dimers via a leucine zipper, which is typically a 7 residue repeat α-helix (heptad). These 
results indicated that AUREO1 possibly dimerizes upon light activation. By fusing AUREO1 
with target proteins, we could potentially take advantage of the light regulated dimerization 
to control protein-protein interactions with light. It could  provide us with a powerful 
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genetically encoded tool to control protein-protein interactions or protein activities in living 
cells with high spatial and temporal resolution. 
 
 
Figure 2 Varying topology structures of coiled coils. Heptad positions (denoted abcdefg) 
are shown in small letters. Predominantly hydrophobic and predominantly polar/charged 
residues are colored with gray and orange, respectively. A, the canonical 3-4 heptad repeat, 
in which hydrophobic residues are located at a and g positions, is found for many coiled coils 
including dimers, trimers, and tetramers. B, An antiparallel tetramer with a 3-3-1 repeat. C. A 
parallel seven-helix coiled coil with a 3-1-2-1- hydrophobic pattern16. 
 
A leucine zipper, which is a very common structure found in transcription factors, is 
typically a 7 residue repeat α-helix (heptad). The heptad repeat  typically has hydrophobic 
residues at a and d position for interactions, and polar/charged residues at e and g position 
(Figure 2). A large number of structural variations are found among coiled coils, such as 
dimers, trimers, tetramers and pentamers. Their helix orientations and alignments may vary 
as well as they can form homocomplexes or heterocomplexes. Protein designers have shown 
great interest in the coiled coil structures, which were among the first rationally designed 
structures16.  Hydrophobic-polar patterning imposes association of helices, and charge 
patterning and other features can be used to confer specificity. For example, 
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homodimerization could be engineered to heterodimerization by making one helix basic and 
another acidic17,18 Besides this, they could be engineered for various purposes18,19, such as 
increasing binding affinity.  
In this study, we propose to develop blue light regulated dimerization based on 
AUREO1. This system will provide a platform to control protein-protein interactions by light 
within seconds and subcellular dimension. It has several advantages, such as fast response, 
reversibility, and no requirement for exogenous cofactors. The leucine zipper domain, with 
potential in various engineering possibilities, such as homodimerization or 
heterodimerization, different kinetics, also could provide a wide application to control 
protein-protein interactions in living cells. 
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CHAPTER 2 
RESULTS AND DISCUSSION 
2.1 Characterization of light regulated dimerization of AUREO1 
To develop a light regulated protein-protein interaction based on AUREO1, we first 
investigated whether the dimerization of AUREO1 is light regulated. It was previously 
reported15 that AUREO1 contains a bZIP (basic region + leucine zipper) domain and LOV 
domain. Typically the basic region binds to the DNA major groove while the leucine zipper 
dimerizes. Therefore we propose that portions of AUREO1 containing a leucine zipper and 
LOV domain (F144-K348) are sufficient for dimerization. 
As showed in Figure 3A, we labeled the AUREO1 (F144-K348) containing leucine 
zipper and LOV domains with His-Myc (HM) tag or Flag-mVenus (FV) tags and studied 
their dimerization by co-immunoprecipitation (co-IP). Dimerization of AUREO1was 
examined in HEK 293 cells coexpressing HM and FV tagged AUREO1 (F144-K348). Two 
groups were examined at the same time with ambient light activation or without light 
activation (performed under red light). Cell lysates were co-immunoprecipitated with anti-
Flag beads and detected with anti-Myc or anti-mVenus in the following western blotting. As 
showed in Figure 3B, HM-AUREO1 was detected in the co-IP with ambient light activation, 
which means HM-AUREO1 co-immunoprecipitated with FV-AUREO1. However, there was 
no co-IP of HM-AUREO1 detected by anti-Myc in the dark. This indicated that AUREO1 
(F144-K348) was sufficient for light regulated dimerization. The ambient light was sufficient 
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to activate the dimerization of AUREO1 in the in vitro biochemical studies. When the 
AUREO1 is in the dark without light activation, it does not dimerize. 
 
Figure 3 AUREO1 (F144-K348) is sufficient for light regulated dimerization. A, 
AUREO1 (F144-K348) was tagged with Flag-mVenus (FV) or His-Myc (HM) respectively. 
B, AUREO1 (F144-K348) dimerizes upon light activation, but not in the dark. HM-
AUREO1 was detected by anti-Myc and FV-AUREO1 was detected by anti-mVenus. 
 
Furthermore, we investigated which regions are critical for the light regulated 
dimerization of AUREO1. It has been known that the leucine zipper domain forms a parallel 
or anti-parallel coiled-coil motif that functions as a flexible DNA binding arms for 
transcription factors20. To study if the leucine zipper is involved in the dimerization of 
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AUREO1, we deleted the leucine zipper but only kept the LOV domain (O217-K348) and 
tagged this with Flag-mVenus (Figure 4A). Using a similar strategy, as discussed in Figure 3, 
we studied the role of the leucine zipper with co-IP assay. As showed in Figure 4B, LOV 
domain alone (O217-K348) does not dimerize with AUREO1 (F144-K348), indicating that 
the leucine zipper is required for the dimerization of AUREO1. In addition, as a 7 residue 
repeat α-helix, the leucine zipper normally dimerizes via hydrophobic interactions in a and d 
positions19. 
 
Figure 4  Both the leucine zipper and the LOV domain are critical for light regulated 
dimerization of AUREO1.  A, the constructs used in the co-IP experiments to characterize 
the light regulated dimerization of AUREO1. B, deletion or mutations of the critical residues 
on the leucine zipper destroys the dimerization. Cysteine 254 to Alanine mutation destroys 
the dimerization too. C, deletion of the C-terminus (D323-K348) leads to dimerization 
independent of light regulation. 
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To test if the AUREO1 dimerizes via the hydrophobic interactions between the 
leucine zipper motifs, we introduced site mutations in the a and d positions. The residues 
leucine 156, asparagine 160 and leucine 163 of AUREO1  (F144-K348) were mutated to 
alanine and tagged with Flag-mVenus (FV-AAA). As showed in the co-IP in Figure 4B, the 
dimerization of AUREO1 was destroyed by the site mutations. It suggests that the AUREO1 
dimerizes by the hydrophobic interactions of its leucine zipper motif. 
Although there is no crystal structure of AUREO1, sequence blast shows that it may 
have a   structure similar to the LOV2 domain from Arabidopsis. AUREO1 has a cysteine at 
residue 254, which aligns with cysteine 450 of LOV2. This led to our hypothesis that 
AUREO1 responds to light activation by binding to flavin mononucleotide (FMN) via 
residue cysteine 254. To test this hypothesis, we mutated residue cysteine 254 to alanine and 
tagged with Flag-mVenus for a co-IP test. As showed in Figure 4b, FV-C254A binds to HM-
AUREO1 very weakly. The binding affinity is much lower than for wild type protein.  
Therefore, we believe that the LOV domain responds to light activation by binding to FMN 
via its cysteine 254.  
We wonder how the LOV domain binding to FMN leads to the dimerization of the 
leucine zipper domain. Interestingly, Aureochrome has two homologs AUREO1 and 
AUREO2. Although they have similar motifs and sequences, only AUREO1, but not 
AUREO2, binds to FMN, indicating that only AUREO1 is regulated by light15. Comparing 
these two homologs, AUREO2 lack ten amino acids (D323-Q332) in the c-terminus, which is 
likely a α-helix predicted by second structure prediction. We propose the hypothesis that the 
leucine zipper is blocked by the C-terminus of AUREO1 in the dark. When it is exposed to 
light activation, LOV domain binding to FMN leads to conformational change and further 
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releases the block of the leucine zipper. To test this hypothesis, we compared the light 
regulation of AUREO1 with or without the C-terminus (D323-K348).  As showed in Figure 
4C, AUREO1 (F144-K348) only dimerize when it is activated by light. Meanwhile, 
AUREO1 (F144-D323) always dimerizes, even without light activation. It indicates there is 
an interaction between the leucine zipper and C-terminus and the dimerization of leucine 
zipper is blocked. Conformational change of the LOV domain caused by binding to FMN 
diminishes this interaction and releases the block. 
 
Figure 5 The autoinhibition model of the light regulated dimerization of AUREO1. To 
sum up, AUREO1 (F144-K348), which mainly contains a leucine zipper and LOV domain, is 
sufficient for light regulated dimerization. Both the leucine zipper and LOV domain are 
critical for the dimerization. Deletion of the leucine zipper or site mutations at critical 
positions destroys the dimerization. It is highly possible that the C-terminus blocks the 
dimerization of the leucine zipper domain. Activated by light, the LOV domain binds to the 
FMN and goes through a conformational change, which releases the blockage of the C-
terminus leucine zipper and further leads to the dimerization. We propose the auto-inhibition 
model to explain the light regulated dimerization of AUREO1 as showed in figure 5. A 
crystal structure of the AUREO1 in the dark will provide more accurate explanations and 
insight about the model. 
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2.2 Engineering AUREO1 to control heterodimerization rather than homodimerization  
One advantage of developing light regulated protein-protein interactions with 
Aureochrome relies on its leucine zipper, which is critical for the dimerization. The leucine 
zipper widely exists in transcription factors for dimerization interaction. Previous studies 
have shown that engineering could be used to alter the dynamics, affinities, or switch from 
homodimerization to heterodimerization. If we could engineer Aureochrome to produce 
herterodimerization, this light regulated protein-protein interactions system would provide far 
wider applications.  
As shown in Figure 6A, the leucine zipper is a 7 repeat α-helix (view from top to 
bottom). Residues at positions a and d are responsible for hydrophobic interactions. Besides 
this, positively or negatively charged residues at positions e and g could interact with each 
other. It has been shown that homodimerization of leucine zippers can  be converted to 
heterodimerization by introducing salt bridges at positions e and g17. To engineer 
Aureochrome to produce heterodimerization, we designed several pairs of salt bridge (R-E or 
K-E) mutations at positions e and g in different repeats. Then we tested if they can form 
heterodimers but not homodimer, using co-IP experiments similar to what we did previously. 
With extensive trials, we finally found that introduction of an R-E salt bridge at residues 
E159 and K164 generated constructs that worked as a pair of heterodimers. 
We mutated E159 and K164 to R or E, and tagged them with Flag-mVenus or His-
Myc respectively. The denotation is shown in Figure 6B. With strategy similar to that applied 
previously, we investigated the dimerization of the EE and RR mutants. We found that HM-
EE and FV-RR dimerize upon light activation but not in the dark, which is very similar to the 
dimerization of HM-AUREO1 and FV-AUREO1. Moreover, the  
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Figure 6 AUREO1 is engineered to light regulated heterodimerization by introducing 
salt bridges at positions a and g. A, the leucine zipper is typically a 7 repeat α-helix (from 
top to bottom view). Heptad positions (denoted abcdefg) are shown in small letters. 
Predominantly hydrophobic and predominantly polar/charged residues are colored in gray 
and orange, respectively. B, the constructs of the heterodimerization pairs. C, the co-IP 
results of homo- and hetero-dimerization. HM: His-Myc; FV: Flag-mVenus; EE: AUREO1 
(F144-K348, K164R); RR: AUREO1 (F144-K348, E159R, K164R). 
 
heterodimerization affinity of HM-EE and FV-RR is comparable to that of HM-AUREO1 
and FV-AUREO1. On the other hand, neither the dimerization of HM-EE and FV-EE or 
HM-RR and FV-RR is comparable to that of HM-AUREO1 and FV-AUREO1. We did see 
some low levels of homodimerization for the EE and RR pairs with long exposure. However, 
the dimerization affinities were much lower than wild type AUREO1. This suggests that 
introduction of EE and RR mutations converted the homodimerization into 
heterodimerization. Moreover, it reduced the homodimerization affinity significantly, 
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possibly by the repulsion of the charged residues. The heterodimer pair provides us a great 
module to use light to control two different target proteins interacting with each other, but not 
with themselves. 
To sum up, we successfully engineered AUREO1 from a homodimerization to a 
heterodimerization domain by introducing the salt bridge R-E at E159 and K164. Both 
mutants AUREO1 (F144-K348, E159R, K164R) and AUREO1 (F144-K348, K164E) have 
no or much lower dimerization affinities. 
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2.3 Test the heterodimerization of AUREO1 in living cells 
To regulate protein-protein interactions with AUREO1 in living cells, we needed to 
verify the interactions of AUREO1 in vivo as a proof of principle. We proposed a membrane 
translocation system to investigate the dimerization of AUREO1 in mammalian cells. As 
showed in Figure 7, we tagged one of the heterodimerizing pair with a fluorescent protein 
(such as GFP) and anchored it on the plasma membrane with a membrane localization tag. 
We then tagged the other member of the heterodimer pair with another fluorescent protein 
with a different spectrum, for example mCherry. Without light activation in the dark, the 
AUREO1 with membrane localization tag should localize on the membrane while the other 
AUREO1 without membrane localization tag should localize in the cytoplasm. After light 
activation, if the AUREO1 dimerizes in living cells, the AUREO1 without membrane 
localization tag will be translocated to the membrane. 
 
Figure 7 Testing light regulated dimerization of AUREO1 in vivo with a membrane 
translocation system.  Leucine zipper is shown as a green α-helix.  
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Figure 8 Testing AUREO1 dimerization in HEK283 cells with membrane translocation 
system. A, without membrane tag, AUREO1 localizes in the cytosol evenly, while it 
localizes on the membrane when it is fused with a Lyn membrane tag. B, left panel, co-
expression of Lyn-mVenus-AUREO1 (F144-K348, K164E) and mKO2-AUREO1 (F144-
K348, E159R, K164R); right panel, co-expression of Lyn-mVenus-AUREO1 (F144-D323, 
K164E) and mKO2-AUREO1 (F144-D323, E159R, K164R). 
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Considering that the C-terminus of AUREO1 is involved in the light regulation, we chose the 
N-terminus membrane localization signal from Lyn kinase. As showed in Figure 8A, 
mVenus-AUREO1 (F144-K348, K164E) localizes in HEK 293 cells uniformly, while Lyn-
mVenus-AUREO1 (F144-K348, K164E), which has the membrane localization signal, 
mostly localizes on the plasma membrane, as showed by confocal imaging. We co-expressed 
Lyn-mVenus-AUREO1 (F144-K348, K164E) and mKO2-AUREO1 (F144-K348, E159R, 
K164R) in HEK293 cells and they localized on the membrane or in the cytosol respectively 
(as showed in Figure 8B, left panel). We activated the cells with ambient light for up to 10 
minutes but saw no membrane translocation. We also tried other light sources such as 473 
nm or 488 nm lasers, again with no membrane translocation after light activation. To rule out 
the possibility that the activation of AUREO1 dimerization needed a long time, we in 
investigated the dimerization in vivo by co-expression of lit state mutants. As showed in 
Figure 4C and 5, it is known that deletion of D323-K348 leads to the constitutive 
dimerization of AUREO1 with or without light activation, which suggests AUREO1 (F144-
D323) mutants could be used as lit state mutants. We co-expressed Lyn-mVenus-AUREO1 
(F144-D323, K164E) and mKO2-AUREO1 (F144-D323, E159R, K164R) in HEK293 cells. 
As shown in Figure 8B (right panel), although Lyn-mVenus-AUREO1 (F144-D323, K164E) 
localizes to the membrane clearly, mKO2-AUREO1 (F144-D323, E159R, K164R) is still 
uniformly distributed in the cytosol, indicating there is no dimerization in the living cells. 
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Figure 9 Optimization of the membrane translocation system. 
 A, co-expression of Lyn-mVenus-5GS-AUREO1 (F144-D323, K164E) and mCherry-5GS-
AUREO1 (F144-D323, E159R,K164R). Left panel: mVenus channel; right panel: mCherry 
channel. B, co-expression of Lyn-mVenus-AUREO1(F144-D323, K164E) and Myc-
AUREO1 (F144-D323, E159R, K164R). Left panel: immunoblotting by anti-mVenus; right 
panel: immunoblotting by anti-Myc. C. co-expression of AUREO1 (F144-D323, K164E)-
mCherry-CAAX and mVenus- AUREO1 (F144-D348, E159R, K164R). Left panel: mCherry 
channel; right panel: mVenus channel. All the images were performed with confocal 
microscopy. 
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There are several possibile explanations for the contradictory results in the co-IP experiments 
and live cell imaging. Firstly, the bulky fluorescent proteins may inhibit or weaken the 
dimerization of the AUREO1. We introduced a series of GS linkers between the fluorescent 
proteins and AUREO1 to increase the flexibility between the fluorescent protein and the 
leucine zipper domain. However, even with co-expression of lit state mutants, there was no 
membrane translocation in living cells. Figure 9A shows the co-expression of Lyn-mVenus-
5GS-AUREO1 (F144-D323, K164E) and mCherry-5GS-AUREO1 (F144-D323, E159R, 
K164R) which have a GSGSGSGSGS (5GS) linker between the fluorescent proteins and 
AUREO1. Other pairs with 1GS, 2GS, 3GS or 4GS linker did not show membrane 
translocation either (data not shown).  
In addition, we deleted the fluorescent proteins and studied the membrane 
translocation with immunostaining. We co-expressed membrane tagged Lyn-mVenus-
AUREO1 (F144-D323, K164E) and Myc-AUREO1 (F144-D323, E159R, K164R), which 
were the same constructs used in the co-IP experiments except that they had the additional 
membrane localization tag. We fixed the cells and immunostained with anti-mVenus and 
anti-Myc and imaged with confocal microscopy. As showed in Figure 9B, the construct Lyn-
mVenus-AUREO1 (F144-D323, K164E) was localized on the membrane clearly. However, 
the co-expressed Myc-AUREO1 (F144-D323, E159R, K164R) was not recruited to the 
membrane but remained in the cytosol homogenously, indicating that these two constructs 
did not dimerize in cells.  
Thirdly, the N-terminus membrane localization signal might influence the 
dimerization of AUREO1 in live cells. We replaced it with a CAAX box which is a C-
terminus membrane localization  sequence and tested with a similar membrane translocation 
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system as shown in Figure 2.5. We co-expressed AUREO1 (F144-D323, K164E)-mCherry-
CAAX and mVenus-AUREO1 (F144-D348, E159R, K164R) in HEK293 cells and 
investigated with confocal microscopy. As showed in Figure 9C, the protein with CAAX 
(membrane localization signal) localized on the membrane clearly. However, mVenus-
AUREO1 (F144-D323, E159R, K164R) was not recruited to the membrane and stayed in the 
cytosol evenly, suggesting that there was no dimerization between these two co-expressed 
constructs. 
Although we tried different ways to optimize the translocation system, including 
different activation methods, various linkers, different membrane tags and orientations etc, 
we did not detect membrane translocation in living cells. It could be possible that the 
dimerization of AUREO1 is different when it is anchored to the membrane. Our results could 
also be due to the sensitivity of the microscopy detection. For example, if there is only a 
small portion of the AUREO1 dimerizing, we may not detect the accumulation of AUREO1 
on the membrane. Therefore, we propose several strategies to further investigate the 
dimerization of AUREO1 in living cells as we will discuss in Chapter 2.4.  
21 
 
2.4 Future directions 
In this study, we investigated the light regulated dimerization of AUREO1 with co-IP 
experiments and successfully engineered AUREO1 to heterodimerize by introducing salt 
bridges. We further tested the dimerization of AUREO1 in live cells with membrane 
translocation systems. Although we tried multiple ways to activate the dimerization and 
different combinations of construct, linker or membrane location tag, we detected no light 
regulated membrane translocation in living cells. There are several possible reasons. For 
example, it is possible that the dimerization of AUREO1 varies when it is distributed in the 
cytosol or anchored on the membrane. Besides, the current method we use may not be 
sensitive enough to detect the change of protein localization. For example, if only a very 
small portion of the AUREO1 is recruited to the membrane by dimerization, the scope may 
not be sensitive to detect the subtle change. 
In future study, we propose strategies to study the AUREO1 dimerization in living 
cells. One strategy is the luciferase-based protein complementation assay, which is thought to 
have the most sensitive and highest dynamic range among protein-protein interaction 
detection methods  in living cells, better than fluorescence resonance energy transfer (FRET) 
and bioluminescence resonance energy transfer (BRET)21. As shown in Figure 10A, 
AUREO1 will be fused with the N-terminal domain of luciferase (NLuc) or the C-terminal 
domain of luciferase (CLuc) respectively and co-expressed in cells. Before light activation, 
NLuc and CLuc are separated and do not interact with each other, therefore the luminescence 
is low and close to background levels. Upon light activation the AUREO1 dimerizes and 
NLuc and CLuc will be brought close, which leads to the increase of the luminescence 
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produced by luciferase. Vice versa, the luciferase activity decreases when the AUREO1 
dissociates. 
 
Figure 10 Other systems to investigate the dimerization of AUREO1 in living cells. 
The leucine zipper domain is shown as green α-helix. A, split luciferase complementation 
assay. Luciferase is split into N-terminal domain (NLuc) and C-terminal domain (CLuc). B, 
split Cre-loxP system. The arrow shows the loxP recombination site. The red STOP sign 
shows the stop codon. Cre protein is split into N-terminal domain (CreN) and C-terminal 
domain (CreC). 
Similarly, we could also use split Cre-loxP system which was initially used in 
activating gene expression in vivo and in vitro22,23. It could also be used to delete DNA 
sequences in selected cell types of transgenic animals at high efficiency24. It has been shown 
that the Cre recombinase can be split into two polypeptides (N-Cre and C-Cre, as showed in 
Figure 10B). Both N-Cre and C-Cre do not have detectable recombination activity until they 
interact with each other25,26. Before light activation, the STOP codon prevents the 
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downstream GFP from transcription. Upon light activation, AUREO1 dimerizes to recruit 
CreN and CreC together,  which will function normally. The STOP codon will be removed 
by the loxP site recombination and GFP will start to express, which could be detected by 
fluorescence microscopy. 
With these systems, we could not only test the dimerization of AUREO1 in living 
cells, but also provides examples of controlling protein-protein interactions and protein 
activities in vivo. This could be further applied to controlling other protein-protein 
interactions or protein activities with optimization.  
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CHAPTER 3 
CONCLUSIONS 
In this study, we successfully characterized the light regulated dimerization of 
AUREO1. With co-IP experiments, we found that the AUREO1 (F144-K348) containing the 
leucine zipper and LOV domain is sufficient for the light regulated dimerization of AUREO1. 
Destroying the leucine zipper interactions with deletions or mutations abolishes the 
dimerization. Critical site mutation at cysteine decreases the dimerization dramatically. These 
results suggest that both the leucine zipper and the LOV domain are critical for light 
regulated dimerization. In addition, deletion of the C-terminus (from D323 to K348) leads to 
dimerization even in the dark, indicating that an auto-inhibition between the leucine zipper 
and C-terminus might be involved in the light regulation. 
Furthermore, we successfully engineered AUREO1 to convert it from a 
homodimerizer to heterodimerizer by introducing salt bridges. Based on previous works on 
leucine zipper engineering and some trials, we found that residues E159 and K164 are critical 
for  dimerization. Introducing R-E salt bridges at these sites leads to heterodimerization but 
no or very weak homodimerization. These mutants potentially provide a platform for wider 
applications. 
In addition, we investigated the dimerization of AUREO1 in living cells with a 
membrane translocation system. With AUREO1 anchored on the membrane or even 
distributed in the cytosol, we expected to see the AUREO1 was recruited to the membrane 
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upon dimerization. We tagged the constructs with different fluorescent proteins and detected 
them by confocal microscopy or immunostaining. However, we did not see a membrane 
translocation with extensive trials, including different ways to active the dimerization, 
various linkers between AUREO1 and fluorescent proteins or membrane tags, and different 
membrane tags. In future study, we proposed two ways to investigate the dimerization of 
AUREO1 in living cells, including split luciferase complementation assay and split Cre-loxP 
system.  
Characterization of the light regulated dimerization of AUREO1 established a 
possible platform for controlling protein-protein interactions. Engineering heterodimerization 
greatly widened the potential applications. Further verification of dimerization of  AUREO1 
in living cells will provide a very important genetically encoded platform that can be 
activated easily with common light sources. With future improvement to the dynamic range, 
efficiency and binding affinity by engineering the leucine zipper and LOV domains, we 
expect these modules to be useful for understanding sophisticated biological questions by 
precisely controlling protein-protein interactions temporally and spatially with light. 
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CHAPTER 4 
METHODS AND MATERIALS 
 
DNA cloning. The cDNA encoding the AUREO1 of Vaucheria frigida was a gift 
from Dr. Hironao Kataoka15. AUREO1 was cloned into pTriEX vectors with His-Myc or 
Flag-mVenus. Lyn membrane tag was fused with AUREO1 by extension PCR. Site specific 
mutations were introduced by overlap extension PCR27.  Fluorescent proteins mVenus, 
mCherry and mKO2 were inserted with a short GS linker to monitor expression and 
subcellular localization. Phusion High-fidelity DNA polymerase (NEB) was used in PCR 
reactions and all plasmids were verified by DNA sequencing. 
Cell culture. HEK293 cells were maintained in DMEM containing 10% FBS 
following the supplier’s culturing instructions. Cells were transfected transiently for 16-20 
hours using FuGENE 6 (Roche) for co-IP assay or imaging.  
Co-IP assay. The co-IP assay were adopted from a previous work form our lab7. 
Flag-mVenus tagged AUREO1 and His-Myc tagged AUREO1 constructs were co-expressed 
in HEK293 cells by transient transfection using FuGENE 6 (Roche). The cells were lysed in 
50mM Tris pH 7.5, 150 nM NaCl and 1% Trition X-100 (lysis buffer) with addition of 
EDTA-free protease inhibitor cocktail (Roche) for 10 minutes at 4 °C. After centrifugation 
for 2 minutes at 4 °C, the supernatants were incubated with Flag/M2-agarose (Sigma) at 4 °C 
for 1 hour. The supernatants was washed with lysis buffer for 3 times and eluted with lysis 
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buffer containing 200µg/ml 3X Flag peptide (Sigma). All procedures were done at 4 °C 
under red light (in the dark) or ambient light, facilitated by Handee spin columns (Pierce). 
The purified protein complexes as well as cell lysates were fractionated on 4-12% NuPAGE 
pre-cast gels (Invitrogen) followed by western blot analysis using antibodies against mVenus 
(JL-8, Clontech, 1:5000 dilution) and Myc (9E10, Sigma, 1:1000 dilution). 
Live cell imaging. Cells for live cell imaging were seeded on coverslips coated with 
5 µg/ml fibronectin in Ham’s F-12K medium free of Phenol red and containing 2% FBS. 
Coverslips were mounted in an Attofluor live cell chamber (Invitrogen) placed on a 
microscope stage with a heated stage adaptor (Warner).  
Immunostaining. Cells were washed with media without serum and 2X PBS and 
then blocked with PBS containing 1% BSA for 15 minutes and followed by 2X washes with 
PBS. Cells were fixed in PBS containing 4% paraformaldehyde (PFA) for 20 minutes and 
washed for 3 times with PBS. Then the cells were permeabilized with 0.2% Trition X-100 in 
PBS for 10 minutes and washed for 3 times with PBS. Fixed and permeabilized cells were 
incubated with primary antibody dilution in PBS-BSA for 1 hour at room temperature or 4 °C 
overnight and then washed for 2 times with PBS. Then the cells were incubated with 
secondary antibody dilution containing a fluorescent label for 30 minutes in the dark and 
washed with PBS for 3 times.  
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